Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.59
+0.8%
$3.06
$2.38
$5.54
$155.09M-0.15430,573 shs490,653 shs
Organogenesis stock logo
ORGO
Organogenesis
$5.15
+0.6%
$4.43
$2.45
$6.71
$653.33M1.761.40 million shs314,198 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$7.12
-1.4%
$5.66
$2.21
$7.46
$619.41M0.18926,122 shs1.26 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$6.96
-1.6%
$5.51
$1.87
$11.40
$609.08M-0.051.16 million shs912,087 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-0.39%+0.39%-15.18%-14.90%-9.82%
Organogenesis stock logo
ORGO
Organogenesis
+5.79%+14.54%+7.34%+84.84%+74.74%
Rezolute, Inc. stock logo
RZLT
Rezolute
+0.28%+3.74%+17.21%+76.53%+54.60%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+2.61%+4.59%+22.96%+126.60%-8.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1.7135 of 5 stars
3.41.00.00.02.71.70.0
Organogenesis stock logo
ORGO
Organogenesis
4.2688 of 5 stars
3.31.00.04.32.94.20.6
Rezolute, Inc. stock logo
RZLT
Rezolute
3.4789 of 5 stars
3.63.00.00.04.04.20.0
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.7949 of 5 stars
3.31.00.04.12.33.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.75
Moderate Buy$10.00286.10% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5045.63% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
3.17
Buy$12.5075.56% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63124.50% Upside

Current Analyst Ratings Breakdown

Latest ELDN, ORGO, RZLT, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/25/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$0.84 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.36$0.22 per share23.19$1.84 per share2.80
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$2.19 per shareN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$3.49 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)

Latest ELDN, ORGO, RZLT, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/18/2025Q4 2025
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.22N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.23-$0.13+$0.10-$0.13N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/5/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.28-$0.26+$0.02-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
8.12
8.12
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
8.43
8.43
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
24.70
24.70

Institutional Ownership

CompanyInstitutional Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.39%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4087.00 million71.00 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.51 million86.20 millionNot Optionable

Recent News About These Companies

Weight-Loss Wasteland: 5 Obesity Assets That Failed
Terns (TERN) Q2 Net Loss Narrows 16%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$2.59 +0.02 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$2.62 +0.03 (+0.97%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$5.15 +0.03 (+0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$5.14 -0.01 (-0.10%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$7.12 -0.10 (-1.39%)
Closing price 04:00 PM Eastern
Extended Trading
$7.09 -0.03 (-0.41%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$6.96 -0.11 (-1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$6.96 0.00 (0.00%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.